Valion Bio (VBIO) Total Liabilities (2021 - 2026)
Valion Bio (VBIO) posted quarterly Total Liabilities of $7.4 million for Q4 2025, up 2635.29% year-over-year from $272000.0 in Q4 2024, and up 1066.14% quarter-over-quarter from $638000.0 in Q3 2025.
Valion Bio (VBIO) Total Liabilities (2021 - 2026) Analysis & Trends
Valion Bio's Total Liabilities history runs 5 years deep, the most recent figure standing at $7.4 million for Q4 2025.
- In Q4 2025, Total Liabilities rose 2635.29% year-over-year to $7.4 million; the TTM figure through Dec 2025 stood at $7.4 million (up 2635.29% YoY), while the FY2025 annual figure was $7.4 million, up 2635.29% from the prior year.
- Total Liabilities for Q4 2025 stood at $7.4 million, up from $638000.0 in the prior quarter.
- The five-year high for Total Liabilities was $7.4 million in Q4 2025, with the low at $272000.0 in Q4 2024.
- The 5-year median for Total Liabilities is $1.4 million (2023), against an average of $1.7 million.
- The sharpest annual moves came in 2024 and 2025: Total Liabilities slumped 82.75% in 2024, then jumped 2635.29% in 2025.
- Valion Bio's Total Liabilities stood at $1.8 million in 2021, then climbed by 27.27% to $2.2 million in 2022, then declined by 29.76% to $1.6 million in 2023, then plunged by 82.75% to $272000.0 in 2024, then surged by 2635.29% to $7.4 million in 2025.
- Business Quant data shows VBIO's Total Liabilities at $7.4 million in Q4 2025, $638000.0 in Q3 2025, and $821000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 10.03 Bn |
| 10 | Valion Bio | 404,585.64 | -1.80 Mn | -45,000.00 | 20.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.59 Mn |
| Dec 31, 2025 | 7.44 Mn |
| Sep 30, 2025 | 638,000.00 |
| Jun 30, 2025 | 821,000.00 |
| Mar 31, 2025 | 741,000.00 |
| Dec 31, 2024 | 272,000.00 |
| Sep 30, 2024 | 560,000.00 |
| Jun 30, 2024 | 591,000.00 |
| Mar 31, 2024 | 1.13 Mn |
| Dec 31, 2023 | 1.58 Mn |
| Sep 30, 2023 | 1.24 Mn |
| Jun 30, 2023 | 1.44 Mn |
| Mar 31, 2023 | 1.90 Mn |
| Dec 31, 2022 | 2.25 Mn |
| Sep 30, 2022 | 2.44 Mn |
| Jun 30, 2022 | 2.84 Mn |
| Mar 31, 2022 | 1.60 Mn |
| Dec 31, 2021 | 1.76 Mn |